| Literature DB >> 32397342 |
Sylvia Drazilova1, Pavol Kristian2, Martin Janicko3, Monika Halanova4, Dominik Safcak5, Patricia Denisa Dorcakova2, Maria Marekova6, Daniel Pella7, Andrea Madarasova-Geckova8, Peter Jarcuska3.
Abstract
Background: The aim of our work is to objectify the manner of transmission of HBV infection in young adult and middle-aged Roma people who live in the settlements.Entities:
Keywords: Roma population; hepatitis B infection; hepatitis B prevalence; horizontal transmission
Year: 2020 PMID: 32397342 PMCID: PMC7246499 DOI: 10.3390/ijerph17093293
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Prevalence of hepatitis B worldwide (adjusted according to [2,15]).
| High Prevalence of Hepatitis B | Moderate Prevalence of Hepatitis B | Low Prevalence of Hepatitis B | |
|---|---|---|---|
| Prevalence of chronic infection | 8%–15% | 2%–7% | 0.1%–1% |
| Prevalence of past infection | 40%–90% | 16%–55% | 4%–15% |
| Perinatal infection | Frequent | Infrequent | Rare |
| Early young age at the time of infection | Very frequent | Frequent | Rare |
| Adolescent and adult age at the time of infection | Infrequent | Frequent | Very frequent |
| Geographic distribution | Southeast Asia, China, Pacific islands, Sub-Saharan Africa, Alaska (Eskimo) | Mediterranean sea, Eastern Europe, Central Asia, Japan, South and Latin America, Middle East | USA, Canada, Western Europe, Australia, New Zealand |
* estimated percentage of total infection among children aged under 1 years old; H estimated percentage of total infection among children aged between 1 and 5 years old.
Description of the whole cohort.
| Absolute(Relative) Count or Median ± IQR (Where Noted) | 95% CI | |
|---|---|---|
| Imprisonment | 46 (10.3%) | 7.8–12.5 |
| IVDU | 2 (0.5%) | 0.08–1.8 |
| Sex for money | 13 (3%) | 1.7–5 |
| Condom use always/almost always | 41 (9.3%) | 0.7–12.4 |
| >4 sexual partners | 52 (11.9) | 9.2–15.3 |
| Tattoo total | 173 (39.1%) | 34.7–43.8 |
| Tattoo privately | 164 (37.1%) | 32.7–41.7 |
| Blood transfusion | 71 (16.7%) | 13.4–20.5 |
| Hepatitis B vaccination | 15 (3.5%) | 2.1–4.5 |
| HBsAg positivity | 55 (12.4%) | 9.7–15.8 |
| Anti HBc IgG positivity | 233 (52.8%) | 48.2–57.4 |
| Persons in living unit (median ± IQR) | 7 ± 4 |
IQR—interquartile range. IVDU—Intravenous drug user.
Characterisation of individual age groups.
| Age Group | ≤25 Years | 25.01–35 Years | 35.01–45 Years | >45 Years | Sig |
|---|---|---|---|---|---|
| Male sex | 36 (42.4%) | 45 (34.4%) | 56 (34.1%) | 22 (32.8%) | 0.541 |
| Age (Mean ± Std. deviation) | 21.8 ± 1.9 | 29.8 ± 3.1 | 39.6 ± 2.2 | 48.3 (2.2%) | <0.0001 |
| Imprisonment | 6 (7.1%) | 10 (7.7%) | 20 (12.3%) | 10 (14.9%) | 0.242 |
| IVDU | 1 (1.2%) | 0 | 1 (0.6%) | 0 | 0.994 |
| Sex for money | 1 (1.2%) | 7 (5.4%) | 3 (1.9%) | 2 (3.0%) | 0.432 |
| Condom use always/almost always | 11 (13.4%) | 15 (11.8%) | 12 (7.4%) | 3 (4.5%) | 0.165 |
| >4 sexual partners | 14 (17.1%) | 18 (14.3%) | 10 (6.3%) | 10 (14.9%) | 0.04 |
| Tattoo total | 30 (35.7%) | 35 (26.9%) | 69 (43.1%) | 38 (56.7%) | 0.0003 |
| Tattoo privately | 29 (34.5%) | 31 (23.8%) | 66 (41.3%) | 37 (55.2%) | 0.0001 |
| Blood transfusion | 6 (7.7%) | 23 (18.5%) | 30 (18.8%) | 12 (20.0%) | 0.123 |
| Hepatitis B vaccination | 2 (2.4%) | 5 (3.8%) | 5 (3.0%) | 3 (4.5%) | 0.657 |
| Persons in living unit (median ± IQR%) | 6 ± 5 | 6 ± 4 | 7 ± 4 | 6 ± 4 | 0.286 |
IQR—interquartile range. IVDU—Intravenous drug user.
Figure 1Anti HBc IgG positivity prevalence according to age, error bars represent 95% CI. p for trend <0.0001.
Figure 2HBsAg positivity prevalence according to age, error bars represent 95% CI, p for trend 0.047.
A comparison of imprisonment, drug use, blood transfusion, sexual behavior and tattoo procedure between HBsAg-positive and -negative Roma people.
|
| HBsAg Positive | HBsAg Negative |
| Multivariate Analysis OR and Significance | |||
|---|---|---|---|---|---|---|---|
| Male sex | 442 | 28 | 50.9% | 127 | 32.8% | 0.01 | 2.083 (95% CI 1.176−3.690); |
| Imprisonment | 435 | 7 | 12.7% | 37 | 9.7% | 0.475 | |
| Drugs total | 439 | 1 | 1.9% | 9 | 2.3% | 1 | |
| Drugs iv | 432 | 0 | 0.0% | 2 | 0.5% | 1 | |
| >4 sexual partners | 427 | 8 | 14.5% | 43 | 11.6% | 0.507 | |
| Sex for money | 429 | 2 | 3.6% | 11 | 2.9% | 0.677 | |
| Tattoo total | 432 | 23 | 44.2% | 147 | 38.7% | 0.453 | |
| Tattoo private | 432 | 20 | 38.5% | 141 | 37.1% | 0.879 | |
| Tattoo parlor | 432 | 3 | 5.8% | 6 | 16.8% | 0.082 | |
| Blood transfusion | 418 | 8 | 14.8% | 61 | 16.8% | 0.845 | |
| Age(years) * | 442 | 35.24 (12.17) | 35.5 (15.5) | 0.864 | |||
* Median (IQR)]; IQR—interquartile range; significance tested by Fisher exact test or Mann–Whitney U test where appropriate. OR—odds ratio; multivariate ORs calculated by logistic regression adjusted for age **. n—number of evaluated patients.
A comparison of imprisonment, drug use, blood transfusion, sexual behavior and tattoo procedure between anti HBc IgG-positive and anti HBc IgG-negative Roma people.
|
| Anti HBcIgG Positive | Anti HBcIgG Negative |
| Multivariate ORs and Significance | |||
|---|---|---|---|---|---|---|---|
| Male sex | 441 | 91 | 39.10% | 64 | 60.8% | 0.069 | |
| Imprisonment | 434 | 31 | 13.50% | 13 | 6.4% | 0.014 | 1.600; (95% CI 0.702–3.646); |
| Drugs total | 438 | 3 | 1.30% | 6 | 2.9% | 0.317 | |
| Drugs iv | 431 | 1 | 0.40% | 1 | 0.5% | 1 | |
| >4 sexual partners | 426 | 23 | 10.20% | 28 | 14.0% | 0.225 | |
| Sex for money | 428 | 8 | 3.50% | 5 | 2.5% | 0.533 | |
| Tattoo total | 431 | 100 | 44.20% | 69 | 33.7% | 0.025 | 1.070; (95% CI 0.663–1.727); |
| Tattoo private | 431 | 95 | 42.00% | 65 | 31.7% | 0.027 | 1.163; (95% CI 0.704–1.833); |
| Tattoo parlor | 431 | 5 | 2.20% | 4 | 2.0% | 1 | |
| Blood transfusion | 417 | 35 | 15.80% | 33 | 16.8% | 0.783 | |
| Age(years) * | 436 | 37.7 (11.98%) | 30.75 (16.12) | <0.0001 | OR for 1-year increment was 1.080; (95% CI 1.054–1.107); | ||
* Median (IQR); IQR—interquartile range; significance tested by Fisher exact test or Mann–Whitney U test where appropriate. ORs—odds ratios; Multivariate ORs calculated by logistic regression adjusted for age and sex ** or for sex ***. n—number of evaluated patients.